- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01889849
Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers
28 juin 2013 mis à jour par: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Comparative Pharmacokinetics and Pharmacodynamics, and Safety of Two Products Containing Recombinant Human Interferon Alpha-2 Conjugated to Polyethylene Glycol in Healthy Volunteers - Phase 1.
This research protocol "Comparative pharmacokinetics and pharmacodynamics of peginterferon Bacterial Intravenous Protein 48 kilodaltons (BIP48) and 40 kilodaltons (40kDa) in healthy volunteers."
This is a Phase I clinical trial which will compare pharmacokinetic and pharmacodynamic parameters, and safety of two products: peginterferon alfa-2a (PEGASYS ®) and BIP48.
It will be a double-blind, randomized crossover with a rest period (wash-out) of 4 weeks.
The study population will be 32 healthy male volunteers to whom will be administered a single dose of 180 microgram of each product, subcutaneously.
The study will have a total duration of 14 days in each treatment step.
The serum concentration of PEG-interferon for both products, measured by enzyme immunoassay (EIA) and by antiviral activity of PEG-interferon, is the main variable.For this purpose 15 samples of each volunteers will be needed.
Clinical and laboratory variables, useful as pharmacodynamics parameters Beta-2 microglobulin (β2M) - 2'5'oligoadenylate synthetase - oligoadenylate synthetase (OAS)- and neopterin) and safety evaluation, will be measured.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
Double-blind study, ie, the volunteers and the study team will not be aware of the product administered.
As the presentations of the two products are different, only the professional who will administer the injections will not be blinded, and will not have contact with volunteers or members of the study team after applying the medication.
Type d'étude
Interventionnel
Inscription (Réel)
32
Phase
- La phase 1
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Rio de Janeiro, Brésil, 21040-360
- Bio-Manguinhos/Fiocruz
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 35 ans (Adulte)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Homme
La description
Inclusion Criteria:
- No history of chronic diseases;
- Preserved oral health;
- No history of acute illness in the last 30 days;
- Absence of significant clinical symptoms and signs on physical examination;
- laboratory tests within normal limits;
- imaging tests within normal limits;
- Seronegative tests for HIV and B and C Hepatitis; Signing the consent form;
- Male;
- Age between 18 and 35 years;
- Body mass index between 19 and 26 (weight in kg / height in meters squared).
Exclusion Criteria:
- Patients with hypersensitivity to Interferon alpha, Escherichia coli-derived products, polyethylene glycol (macrogol), or any constituent salts of these preparations.
- Individuals treated with some type of interferon at any time, prior to the present research.
- History of chronic diseases such as autoimmune diseases, liver failure, decompensated cirrhosis, heart disease, renal failure, diabetes mellitus, thyroid diseases, hemoglobinopathies, cytopenias, history of psychiatric disease, retinopathy, optic neuritis.
- History of acute viral disease in the last 30 days;
- Current use of medications that alter immunity: corticosteroids, immunosuppressants;
- History of known allergy to drugs, including interferon or to any component of the product (at the discretion of the investigator);
- Having undergone surgery during the 6 months prior to study entry; Had donated blood three months prior to study entry;
- History of alcoholism or current use of alcohol;
- Use of other illicit drugs in the past 6 months;
- Participation in a clinical study with previous therapeutic intervention in the year prior to inclusion.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: BIP48
Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks.
Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number.
The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
|
Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
Autres noms:
Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
Autres noms:
|
|
Comparateur actif: Pegasys
Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks.
Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number.
The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
|
Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
Autres noms:
Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety Assessment
Délai: 14 days + least 4 weeks (rest period between each administration) + 14 days
|
Evaluation of safety will be estimated by the analysis of clinical chemistry and hematology (CBC and transaminase) prior to study initiation and at 24, 48, 72, 96, 120, 168 and 336 hours after administration of peginterferon alpha, in each treatment period.
|
14 days + least 4 weeks (rest period between each administration) + 14 days
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Paulo Dornelles Picon, Doctorate, Immunobiological Technology Institute (Bio-Manguinhos)
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- da Silva AMV, Alvarado-Arnez LE, Azamor T, Batista-Silva LR, Leal-Calvo T, Bezerra OCL, Ribeiro-Alves M, Kehdy FSG, Neves PCDC, Bayma C, da Silva J, de Souza AF, Muller M, de Andrade EF, Andrade ACM, Dos Santos EM, Xavier JR, Maia MLS, Meireles RP, Cuni HN, Sander GB, Picon PD, Matos DCS, Moraes MO. Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha. Front Cell Infect Microbiol. 2021 Jul 7;11:656393. doi: 10.3389/fcimb.2021.656393. eCollection 2021.
- Costa MB, Picon PD, Sander GB, Cuni HN, Silva CV, Meireles RP, Goes ACMA, Batoreu NM, Maia MLS, Albuquerque EM, Matos DCS, Saura PL. Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. BMC Pharmacol Toxicol. 2018 Jan 4;19(1):1. doi: 10.1186/s40360-017-0192-z.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 octobre 2010
Achèvement primaire (Réel)
1 août 2011
Achèvement de l'étude (Réel)
1 août 2011
Dates d'inscription aux études
Première soumission
19 juin 2013
Première soumission répondant aux critères de contrôle qualité
28 juin 2013
Première publication (Estimation)
1 juillet 2013
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
1 juillet 2013
Dernière mise à jour soumise répondant aux critères de contrôle qualité
28 juin 2013
Dernière vérification
1 juin 2013
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections transmissibles par le sang
- Maladies transmissibles
- Maladies du foie
- Infections à Flaviviridae
- Hépatite, virale, humaine
- Hépatite chronique
- Hépatite
- Hépatite C
- Hépatite C chronique
- Agents anti-infectieux
- Agents antiviraux
- Peginterféron alfa-2a
- Peginterféron alfa-2b
Autres numéros d'identification d'étude
- ASCLIN 003/2009
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .